Skip to main content
Equibles
CTOR logo

CTOR · Citius Oncology, Inc.

Track CTOR — free

Use CTOR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CTOR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.74 -0.02 (-2.02%) At close · Aug 21
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$70.58M
Shares
92.98M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.74 Open$0.72 Day$0.72–0.75 52W close$0.49–2.17 Avg vol 30d110K Short int399K · 0.4% float · 6.2d Short vol36% DataDec 2022–Aug 2026 Filing10-Q · Aug 14

Up next

FQ4-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg +9%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 15%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +32%
trailing
6-month return −31%
trailing
YTD return −26%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+36% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.43% of float · ▲ +9.4% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
19 holders — near 2-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Fair
EPS growth −10%
Y/Y
Balance sheet $3.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −77%
past year
ATR 11.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
+9% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
15% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+36% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.43% of float · ▲ +9.4% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
19 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $1 · 15% Range high $2
vs 200-day avg -20% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross profit on product revenues 67% the three months ended June 30, 2026 filing —
Finished goods and work-in-process inventory $22.7M as of March 31, 2026 —
Target accounts on formulary or in review 83% fiscal second quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CTOR
Citius Oncology, Inc.
this stock
$70.58M -25.6% — — 0.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.06B +16.6% — — 0.1%
GALDY
Galderma Group AG/ADR
 $49.82B +3.3% — — 0.0%
HLN
Haleon plc
 $43.94B -1.1% — — 0.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
19
% held
15.2%
Net QoQ
-102.5K sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Rising
Shares short
399.4K
Days to cover
6.2d
Change
+34.3K sh
View
Short Volume
Short vol %
36%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
133
Value
$72
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
70.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-24.8M
EPS diluted
$-0.34
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
15
View
Earnings & Events
Investor Relations
Latest news
Citius Oncology Reports Nationwid…
Published
Jul 21, 2026
View

Performance

5D 20D 120D MTD YTD
CTOR -18.3% +32.4% -31.1% +25.6% -25.6%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY -16.9% +28.7% -42.7% +23.1% -37.9%
Key facts CIK 1851484 CUSIP 17331Y109 13F (30d) 19 filings 18 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)